In a bold and very challenging move, thoracic surgeons at Toronto General Hospital (TGH) removed severely infected lungs from a dying mom, keeping her alive without them for six days, so that she could recover enough to receive ...
Jan 30, 2017
0
123
A new method which doubles the usual time donor lungs can remain outside the body can benefit patients, staff and allow retrieval of donor lungs across greater geographical areas, says a study published in The Lancet Respiratory ...
Nov 18, 2016
0
5
Using the results from a computerized mathematical model, Johns Hopkins researchers investigated whether they could improve heart and lung transplantation procedures by transferring patients from low-volume to high-volume ...
Sep 13, 2016
0
21
Cardiac arrhythmia is a common complication following lung transplantation, and one that has a significant negative impact on long-term patient survival, reports a team of UPMC researchers in the largest study of its kind ...
May 26, 2016
0
0
High-volume lung transplant centers have lower transplantation costs and their patients are less likely to be readmitted within 30 days of leaving the hospital following surgery, according to a new study of more than 3,000 ...
Apr 14, 2016
0
0
Michele Coleman lay close to death last fall with end-stage lung disease when she got a second chance at life.
Apr 7, 2016
0
51
Idiopathic pulmonary fibrosis (IPF) is a chronic adult lung disease in which normal lung tissue is slowly replaced by scar tissue, affecting seven to 16 of every 100,000 Americans. Though the name is similar, IPF differs ...
Mar 7, 2016
0
0
To determine patient eligibility for heart transplant, the International Society for Heart Lung Transplantation (ISHLT) maintains a list of criteria, first issued in 2006, that acts as a guideline for physicians. A major ...
Jan 7, 2016
0
0
In solid-organ transplant recipients, the cancer death rate was higher than in the general population in a new study from Ontario, Canada, published online by JAMA Oncology.
Jan 7, 2016
0
0
(HealthDay)—Uptravi (selexipag) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension, a disabling lung disease that often leads to death or the need for lung transplant.
Dec 22, 2015
0
2
